Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Polyrizon Ltd. (PLRZ : NSDQ)
 
 • Company Description   
Polyrizon Ltd. is a development stage biotech company specializing in the development of medical device hydrogels delivered in the form of nasal sprays. Polyrizon Ltd. is based in Raanana, Israel.

Number of Employees: 6

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.72 Daily Weekly Monthly
20 Day Moving Average: 323,196 shares
Shares Outstanding: 5.33 (millions)
Market Capitalization: $3.82 (millions)
Beta:
52 Week High: $765.00
52 Week Low: $0.55
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -33.08% -35.59%
12 Week -99.19% -99.32%
Year To Date -99.87% -99.88%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
5 HA-TIDHAR STREET
-
RAANANA,L3 4366507
ISR
ph: 972-9374-0120
fax: -
ir@polyrizon-biotech.com http://www.polyrizon-biotech.com
 
 • General Corporate Information   
Officers
Tomer Izraeli - Chief Executive Officer
Nir Ben Yosef - Chief Financial Officer
Asaf Itzhaik - Director
Oz Adler - Director
Omer Srugo - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: M79549123
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: -
Next Expected EPS Date: -
Share - Related Items
Shares Outstanding: 5.33
Most Recent Split Date: 5.00 (0.00:1)
Beta:
Market Capitalization: $3.82 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: -  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.00
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
06/30/25 - -
03/31/25 - -
12/31/24 - -
ROA
06/30/25 - -
03/31/25 - -
12/31/24 - -
Current Ratio
06/30/25 - -
03/31/25 - -
12/31/24 - 10.16
Quick Ratio
06/30/25 - -
03/31/25 - -
12/31/24 - 10.16
Operating Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Net Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Pre-Tax Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Book Value
06/30/25 - -
03/31/25 - -
12/31/24 - 315.05
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - -
12/31/24 - 0.00
Debt-to-Capital
06/30/25 - -
03/31/25 - -
12/31/24 - 0.00
 

Powered by Zacks Investment Research ©